Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de avaliação eletrónica de resultados clínicos (eCOA) no Médio Oriente e África

Espera-se que a necessidade de melhorar a conformidade, captar e gerir eficazmente a informação clínica, reduzir custos e aumentar as atividades de I&D impulsione o crescimento do mercado. A Kayentis, uma empresa francesa especializada em soluções electrónicas de avaliação de resultados clínicos (eCOA), receberá aproximadamente 8,3 milhões de dólares em financiamento em Dezembro de 2020. Isto ajudou nos seus objectivos de expansão regional e desenvolvimento de produtos.

A Data Bridge Market Research analisa que o mercado eletrónico de avaliação de resultados clínicos (eCOA), que foi de 57,02 mil milhões de dólares em 2022, deverá atingir os 144,23 mil milhões de dólares até 2030, com um CAGR de 12,30% durante o período de previsão de 2023 a 2030. Para além dos insights sobre os cenários de mercado, tais como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também a análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e estrutura regulatória .

Âmbito e segmentação do mercado de avaliação de resultados clínicos eletrónicos do Médio Oriente e África (eCOA)

Definição de mercado

As avaliações eletrónicas dos resultados clínicos são utilizadas para determinar a condição de um doente, bem como as consequências e o curso de uma doença (eCOA). As avaliações eletrónicas dos resultados clínicos proporcionam visibilidade em tempo real, o que auxilia na adesão ao protocolo, na segurança e participação do doente e na redução do risco do ensaio.

Dinâmica de mercado da Avaliação Eletrónica de Resultados Clínicos (eCOA) no Médio Oriente e África

Motoristas

• Aumento da carga sobre os fabricantes farmacêuticos

As novas técnicas de desenvolvimento de medicamentos dependem cada vez mais da captura electrónica de dados, em vez de procedimentos baseados em papel, para reduzir os custos totais. A recolha de dados utilizando plataformas eletrónicas de avaliação de resultados clínicos melhora a qualidade dos dados, harmoniza as práticas de recolha de dados e proporciona um valor significativo aos seus utilizadores, como a análise de dados. Os serviços eletrónicos de recolha e análise de dados eliminam as desvantagens dos registos em papel e aumentam a adesão dos doentes. Também reduzem o custo da monitorização do local e eliminam o risco de flutuação de dados. Estas soluções fornecem informação simplificada, o que auxilia na melhoria da qualidade dos dados através da recolha de dados de forma estruturada. Espera-se que os benefícios acima mencionados da utilização de avaliações eletrónicas de resultados clínicos aumentem a procura do produto nos próximos anos.

• Aumento das avaliações de resultados clínicos

As avaliações de resultados clínicos (COAs) estão, por isso, a ser utilizadas com maior frequência para avaliar a eficácia de várias terapêuticas para doenças crónicas. Estes têm sido frequentemente cruciais na aprovação regulamentar de medicamentos. A adição de numerosos serviços também a ajudará a crescer. Por exemplo, em junho de 2021, a Signant Health lançou um novo programa de aceleração que reduz os prazos de preparação dos estudos em 50% ou mais, sem comprometer a qualidade dos dados clínicos. Assim, o crescente lançamento de novos programas que beneficiam as empresas na avaliação de estudos de ensaios clínicos irá provavelmente aumentar a procura de soluções electrónicas de avaliação de resultados clínicos, impulsionando assim o crescimento do mercado.

Oportunidades

• Aumento da procura por soluções eletrónicas de avaliação de resultados clínicos

According to a study published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential COVID-19 therapeutics were identified using a combined virtual and experimental screening strategy and selected from a library of nearly 4,000 approved drugs, with hydroxychloroquine (HCQ) as a reference drug. Zuclopenthixol, nebivolol, and amodiaquine have been proposed as potential clinical trial candidates for the early stages of SARS-CoV-2 infection, and remdesivir and favipiravir therapeutics have been proposed as potential adjuvants in COVID-19 treatment. The demand for electronic clinical outcome assessment solutions is expected to increase as the number of clinical trials increases as a result of the repurposing of several medications.

Restraints/Challenges

• High implementation costs

Data privacy issues and expensive implementation costs limit the market's expansion. In addition, in the forecast period of 2023-2030, A lack of favourable reimbursement scenarios in developing economies, high customs duties on medical equipment, and a lack of sufficient infrastructure in low- and middle-income countries are expected to pose challenges to the market.

This electronic clinical outcome assessment (eCOA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electronic clinical outcome assessment (eCOA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Electronic Clinical Outcome Assessment (eCOA) Market

The COVID-19 pandemic hampered clinical study conduct and management in 2020. To address these issues and ensure the continuity of clinical research activities, market stakeholders implemented a variety of initiatives, including the use of eClinical technologies. As a result of the pandemic, clinical trials were digitised. Many sponsors, biopharma companies, medical device companies, and contract research organisations (CROs) have begun to use eClinical systems to collect, manage, and derive meaningful insights from data in a cost-effective and remote manner. Electronic clinical outcome assessment can be used to collect patient data remotely.

Recent Development

• In 2020, Oracle expanded its cloud system to Australia (Melbourne), Japan (Osaka), Saudi Arabia (Jeddah), the Netherlands (Amsterdam), and Canada (Montreal). The market expansion is expected to benefit from increased consumer awareness of its cloud-based applications.

• In 2020, ArisGlobal partnered with Soterius, Inc. to expand its product offering by adding LifeSphere Medical Information and LifeSphere MultiVigilance to its service-oriented technology stack.

Middle East and Africa Electronic Clinical Outcome Assessment (eCOA) Market Scope

The electronic clinical outcome assessment (eCOA) market is segmented on the basis of product, delivery mode, approach, platform and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• On-Premise Solutions
• Cloud Based Solutions
• Web Based Solutions

Delivery Mode

• Web-hosted
• Cloud-based

Approach

• Patient-reported Outcome (PRO)
• Clinician-reported Outcome (CLINRO)
• Observer-reported Outcome (OBSRO)
• Performance Outcome (PERFO)

Platform

• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Medical Device Manufacturers
• Hospitals and Clinical Laboratories
• Consulting Service Companies
• Research and Academia
• Others

End-User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations
• Other End-Users

Electronic Clinical Outcome Assessment (eCOA) Market Regional Analysis/Insights

The electronic clinical outcome assessment (eCOA) market is analyzed and market size insights and trends are provided by country, product, delivery mode, approach, platform and end-user as referenced above.

The countries covered in the electronic clinical outcome assessment (eCOA) market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The electronic clinical outcome assessment (eCOA) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for electronic clinical outcome assessment (eCOA) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the electronic clinical outcome assessment (eCOA) market. The data is available for historic period 2011-2021.

Competitive Landscape and Electronic Clinical Outcome Assessment (eCOA) Market Share Analysis

The electronic clinical outcome assessment (eCOA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to electronic clinical outcome assessment (eCOA) market.

Some of the major players operating in the electronic clinical outcome assessment (eCOA) market are:

• IBM Corporation (U.S.)
• IQVIA (U.S.)
• Medidata Solutions, Inc. (U.S.)
• Clario (U.S.)
• ArisGlobal (U.S.)
• Signant Health (U.S.)
• TransPerfect (U.S.)
• Cloudbyz (U.S.)
• Climedo Health GmbH (Germany)
• ClinCapture (U.S.)
• Oracle Corporation (U.S.)
• Paraxel International Corporation (U.S.)
• eClinical Solutions LLC (U.S.)
• OmniComm Systems, Inc. (U.S.)
• CRF Health (U.S.)
• European Round Table (U.S.)

SKU-52429